Axenfeld-Rieger综合征:从斑马鱼模型到临床结局
回顾性队列研究分析1970-2023年诊断的66例Axenfeld-Rieger综合征(ARS)患者,分为4种表型,42例(64%)诊断为青光眼,33例58眼需降眼压手术。青光眼患者最终最佳矫正视力更差,且与青光眼手术次数线性相关;斑马鱼模型验证了临床鉴定的FOXC1变异。
要点
- ARS患者中64%诊断为青光眼,中位诊断年龄4.2年,青光眼患者初始眼压更高且最终视力更差。
- 小梁切除术联合丝裂霉素C的10年生存率76%(95%CI 47-91),Baerveldt装置为71%(95%CI 47-86)。
- 斑马鱼Foxc1a敲低模型可被人野生型FOXC1 mRNA挽救,但临床变异型FOXC1 mRNA不能挽救。
核心结论
- 在ARS中,青光眼患者最终最佳矫正视力更差,且常需房角旁路手术。
- 斑马鱼模型再现了ARS表型,并验证了临床鉴定的FOXC1变异。
研究设计与样本
- 回顾性队列研究,纳入1970-2023年诊断的ARS患者66例(31例男性),收集眼部诊断、手术、遗传信息和检查结果。
- 手术成功定义为眼压5-20 mmHg、无需额外降眼压手术且无视觉毁灭性并发症。
- 进行斑马鱼活体成像和组织学研究以探究FOXC1变异。
主要发现
- 66例患者就诊中位年龄4.1年(IQR 0.4-13.1),分为4种表型:深前房55例、浅前房4例、角膜混浊3例、虹膜角膜发育不全4例。
- 42例(64%)诊断为青光眼,中位诊断年龄4.2年(IQR 0.3-13.3),33例患者共58眼需降眼压手术。
- 青光眼患者较无青光眼患者初始眼压更高(P<.0001),最终最佳矫正视力更差(P<.01)。
- 末次随访(中位6.1年,IQR 1.6-10.1)时,青光眼患者眼压下降(P<.0001),但降眼压药物使用增加(P<.001)。
- 10年生存率:小梁切除术联合丝裂霉素C为76%(95%CI 47-91),Baerveldt装置为71%(95%CI 47-86)。
关键数值与推荐
- 手术成功标准:眼压5-20 mmHg、无额外降眼压手术、无视觉毁灭性并发症。
- 10年生存率:小梁切除术联合丝裂霉素C 76%(95%CI 47-91),Baerveldt装置71%(95%CI 47-86)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate genetics and outcomes in Axenfeld-Rieger Syndrome (ARS). METHODS: Retrospective cohort study of ARS patients diagnosed 1970-2023. Ocular diagnoses, surgeries, genetic information, and exam findings were collected. Surgery success was defined as IOP of 5-20 mmHg, no additional IOP-lowering surgery, and no visually devastating complications. Live-imaging and histological zebrafish studies were performed to study FOXC1 variants. RESULTS: A total of 66 patients (31 males) presented at median 4.1 years [IQR 0.4, 13.1] and were classified into 4 ARS phenotypes: deep anterior chamber (n = 55), shallow anterior chamber (n = 4), corneal opacification (n = 3), and iridogoniodysgenesis (n = 4). Total 42 patients (64%) were diagnosed with glaucoma at median 4.2 years [IQR 0.3, 13.3] and 58 eyes of 33 patients required IOP-lowering surgery. Patients with glaucoma had higher initial IOP (P < .0001) and worse final BCVA (P < .01) compared to patients without glaucoma. At final follow-up (median 6.1 years [IQR 1.6, 10.1]), patients with glaucoma showed decreased IOP (P < .0001), but increased glaucoma medications (P < .001). Ten-year survival rates were greatest for trabeculectomy with mitomycin C (76% with 95% CI [47, 91]) and Baerveldt devices (71% with 95% CI [47, 86]. Final BCVA was linearly associated with number of glaucoma surgeries (ß=0.15, P < .01, R2 = 0.12). Foxc1a zebrafish morpholino oligonucleotide knockdown, which disrupted ocular and craniofacial development, was rescued by human wildtype FOXC1 mRNA, but not mutant FOXC1 mRNA containing clinically identified variants. CONCLUSIONS: In ARS, patients with glaucoma had worse final BCVA and often required angle bypass surgery. Further, our zebrafish model recapitulated ARS and verified clinically identified FOXC1 variants. NOTE: Publication of this article is sponsored by the American Ophthalmological Society.
引用
- Bohnsack BL, Williams AL, Jacobson A, et al. Axenfeld-Rieger Syndrome: From Zebrafish Models to Clinical Outcomes. Am J Ophthalmol. 2025. PMID: 41242594. doi:10.1016/j.ajo.2025.11.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。